Specialized Disclosure Report (sd)
May 31 2019 - 2:05PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM SD
SPECIALIZED DISCLOSURE REPORT
GlaxoSmithKline plc
(Exact name of Registrant as specified in its charter)
|
England and Wales
|
|
001-15170
|
|
98-0607772
|
|
(State or other jurisdiction
of incorporation)
|
|
(Commission File Number)
|
|
(I.R.S. Employer
Identification No.)
|
GlaxoSmithKline plc
980 Great West Road
Brentford, TW8 9GS
England
(Address of principal executive offices)
Victoria Whyte
Company Secretary
+44 20 8047 5000
(Name and telephone number of this person to contact in connection with this report)
Check the appropriate box to indicate the rule pursuant to which this form is being filed, and provide the period to which the information in
this form applies:
☒ Rule 13p-l under the Securities Exchange Act (17 CFR240.13p-l) for the reporting period from January 1 to December 31, 2018.
Section 1 – Conflict Minerals Disclosure
|
Item 1.01
|
Conflict Minerals Disclosure and Report
|
The Conflict Minerals Report for
GlaxoSmithKline plc (GSK) for the year ended December 31, 2018 is attached as Exhibit 1.01 to this Report and is available on GSK’s website at
https://www.gsk.com/en-gb/about-us/policies-codes-and-standards/
.
GSK’s Conflict Minerals Report is attached as Exhibit 1.01 to this Report.
Section 2 – Exhibits
The following exhibit is filed as a part of this report.
|
|
Conflict Minerals Report for the Year Ended December 31, 2018
|
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the
duly authorized undersigned.
|
|
|
/s/ Iain MacKay
|
|
|
Dated: May 31, 2019
|
Name: Iain MacKay
|
|
|
|
Title: Chief Financial Officer
GlaxoSmithKline plc
|
|
3
GSK (NYSE:GSK)
Historical Stock Chart
From Oct 2024 to Nov 2024
GSK (NYSE:GSK)
Historical Stock Chart
From Nov 2023 to Nov 2024
